ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

• Status: Active, not recruiting
• Trial end date: 2026-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto University, Graduate School of Medicine
• Treatments: Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists

Criteria

Inclusion Criteria:

• Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent under the setting of acute coronary syndrome

• Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and P2Y12 receptor antagonist

Exclusion Criteria:

• Patients requiring oral anticoagulants

• Patients with medical history of intracranial hemorrhage

• Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention

• Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents implanted at the time of enrollment

• Patients confirmed to have no tolerability to clopidogrel before enrollment

• Patients requiring continuous administration of antiplatelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment